<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA Approval on FinanClub</title>
    <link>https://finan.club/tags/fda-approval/</link>
    <description>Recent content in FDA Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Feb 2024 09:04:12 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Fri, 09 Feb 2024 09:04:12 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:33
Chances: Iovance&amp;rsquo;s lead pipeline drug is anticipated to receive FDA approval as the first individualized, one-time cell therapy for certain patients with melanoma. The company is focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.</description>
    </item>
    
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Tue, 06 Feb 2024 09:04:23 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:152
Chances: ImmunityBio, Inc. continues to make significant progress in its clinical-stage immunotherapy treatments, with positive interim results from the QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and timely completion of its Biologics License Application (BLA) resubmission for FDA review.</description>
    </item>
    
    <item>
      <title>GKOS</title>
      <link>https://finan.club/us/gkos/</link>
      <pubDate>Wed, 24 Jan 2024 09:05:58 +0000</pubDate>
      
      <guid>https://finan.club/us/gkos/</guid>
      <description>score:12
Chances: Glaukos Corporation continues to benefit from a robust product portfolio and favorable clinical trial results. The FDA approval of Glaukos&amp;rsquo; iDose TR is likely to reshape glaucoma care, promising proactive and durable treatment. Risks: The insider transaction and sale of shares by the President &amp;amp; COO could raise concerns among investors.</description>
    </item>
    
  </channel>
</rss>
